Patient Advocate's Notes From 8th International Kidney Cancer Symposium

Conclusions on Optimal Systemic Control For High Risk Patients:   - Anti-angiogenic agents are capable of reducing primary tumors, but not consistently.  - There is no evidence that anti-angiogenic agents are anti-metastatic  - Monitoring tools/markers need to be developed that can measure efficacy of anti-metastatic drugs   AS a patient advocate I point out that in the summary table of neoadjuvant trials results for local control: There is a learning curve to use these drugs safely and effectively. The current neoadjuvant therapy approaches were safe in the hands of experienced clinicians... an example is that some patients had incomplete wound healing and had to have their treatment approach altered "on the run."       Emerging Applications of VEGF and mTOR-Targeted Therapy Case Presentation and Background Brian I. Rini, M.D.       Standards of Care and Current Single-Agent Clinical Trials Robert A. Figlin, M.D.       Intermittent Therapy with Tyrosinekinase Inhibitors Viktor Grunwald, M.D.       Therapy Re-Challenge Thomas E. Hutson, D.O., PharmD.       Alternative Dosing Schemas of VEGF and mTOR therapy in metastatic RCC Toni K. Choueiri, M.D., M.S.         Combination Therapy: Exisiting Data and Ongoing Clinical Trials Keith Flaherty, M.D.       Abstract Presentation: Phase II trial of continuous once-daily dosing of suni...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news